Cargando…

An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation

Conscious or moderate sedation is routinely used to facilitate the dental care of the pre- or un-cooperative child. Dexmedetomidine (DEX) has little respiratory depressant effect, possibly making it a safer option when used as an adjunct to either opioids or benzodiazepines. Unlike intranasal (IN) m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hitt, James M., Corcoran, Toby, Michienzi, Kelly, Creighton, Paul, Heard, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978530/
https://www.ncbi.nlm.nih.gov/pubmed/24662315
http://dx.doi.org/10.3390/pharmaceutics6010175
_version_ 1782310584815976448
author Hitt, James M.
Corcoran, Toby
Michienzi, Kelly
Creighton, Paul
Heard, Christopher
author_facet Hitt, James M.
Corcoran, Toby
Michienzi, Kelly
Creighton, Paul
Heard, Christopher
author_sort Hitt, James M.
collection PubMed
description Conscious or moderate sedation is routinely used to facilitate the dental care of the pre- or un-cooperative child. Dexmedetomidine (DEX) has little respiratory depressant effect, possibly making it a safer option when used as an adjunct to either opioids or benzodiazepines. Unlike intranasal (IN) midazolam, IN application of DEX and sufentanil (SUF) does not appear to cause much discomfort. Further, although DEX lacks respiratory depressive effects, it is an α(2)-agonist that can cause hypotension and bradycardia when given in high doses or during prolonged periods of administration. The aim of this feasibility study was to prospectively assess IN DEX/SUF as a potential sedation regimen for pediatric dental procedures. After IRB approval and informed consent, children (aged 3–7 years; n = 20) from our dental clinic were recruited. All patients received 2 μg/kg (max 40 μg) of IN DEX 45 min before the procedure, followed 30 min later by 1 μg/kg (max 20 μg) of IN SUF. An independent observer rated the effects of sedation using the Ohio State University Behavior Rating Scale (OSUBRS) and University of Michigan Sedation Scale (UMSS). The dentist and the parent also assessed the efficacy of sedation. Dental procedures were well tolerated and none were aborted. The mean OSUBRS procedure score was 2.1, the UMSS procedure score was 1.6, and all scores returned to baseline after the procedure. The average dentist rated quality of sedation was 7.6 across the 20 subjects. After discharge, parents reported one child with prolonged drowsiness and one child who vomited at home. The use of IN DEX supplemented with IN SUF provided both an effective and tolerable form of moderate sedation. Although onset and recovery are slower than with oral (PO) midazolam and transmucosal fentanyl, the quality of the sedation may be better with less risk of respiratory depression. Results from this preliminary study showed no major complications from IN delivery of these agents.
format Online
Article
Text
id pubmed-3978530
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-39785302014-04-08 An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation Hitt, James M. Corcoran, Toby Michienzi, Kelly Creighton, Paul Heard, Christopher Pharmaceutics Concept Paper Conscious or moderate sedation is routinely used to facilitate the dental care of the pre- or un-cooperative child. Dexmedetomidine (DEX) has little respiratory depressant effect, possibly making it a safer option when used as an adjunct to either opioids or benzodiazepines. Unlike intranasal (IN) midazolam, IN application of DEX and sufentanil (SUF) does not appear to cause much discomfort. Further, although DEX lacks respiratory depressive effects, it is an α(2)-agonist that can cause hypotension and bradycardia when given in high doses or during prolonged periods of administration. The aim of this feasibility study was to prospectively assess IN DEX/SUF as a potential sedation regimen for pediatric dental procedures. After IRB approval and informed consent, children (aged 3–7 years; n = 20) from our dental clinic were recruited. All patients received 2 μg/kg (max 40 μg) of IN DEX 45 min before the procedure, followed 30 min later by 1 μg/kg (max 20 μg) of IN SUF. An independent observer rated the effects of sedation using the Ohio State University Behavior Rating Scale (OSUBRS) and University of Michigan Sedation Scale (UMSS). The dentist and the parent also assessed the efficacy of sedation. Dental procedures were well tolerated and none were aborted. The mean OSUBRS procedure score was 2.1, the UMSS procedure score was 1.6, and all scores returned to baseline after the procedure. The average dentist rated quality of sedation was 7.6 across the 20 subjects. After discharge, parents reported one child with prolonged drowsiness and one child who vomited at home. The use of IN DEX supplemented with IN SUF provided both an effective and tolerable form of moderate sedation. Although onset and recovery are slower than with oral (PO) midazolam and transmucosal fentanyl, the quality of the sedation may be better with less risk of respiratory depression. Results from this preliminary study showed no major complications from IN delivery of these agents. MDPI 2014-03-21 /pmc/articles/PMC3978530/ /pubmed/24662315 http://dx.doi.org/10.3390/pharmaceutics6010175 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Concept Paper
Hitt, James M.
Corcoran, Toby
Michienzi, Kelly
Creighton, Paul
Heard, Christopher
An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title_full An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title_fullStr An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title_full_unstemmed An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title_short An Evaluation of Intranasal Sufentanil and Dexmedetomidine for Pediatric Dental Sedation
title_sort evaluation of intranasal sufentanil and dexmedetomidine for pediatric dental sedation
topic Concept Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978530/
https://www.ncbi.nlm.nih.gov/pubmed/24662315
http://dx.doi.org/10.3390/pharmaceutics6010175
work_keys_str_mv AT hittjamesm anevaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT corcorantoby anevaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT michienzikelly anevaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT creightonpaul anevaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT heardchristopher anevaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT hittjamesm evaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT corcorantoby evaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT michienzikelly evaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT creightonpaul evaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation
AT heardchristopher evaluationofintranasalsufentanilanddexmedetomidineforpediatricdentalsedation